During the past decade, Cattedra di Ematologia - Azienda Ospedaliera di Careggi conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 7 clinical trials were completed, i.e. on average, 43.8% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 2 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cattedra di Ematologia - Azienda Ospedaliera di Careggi" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 9 trials, followed by "Gruppo Italiano Trapianto di Midollo Osseo" with 8 trials sponsored, "Hoffmann-La Roche" with 8 trials sponsored, "Fondazione Italiana Linfomi ONLUS" with 6 trials sponsored and "Northern Italy Leukemia Group" with 6 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cattedra di Ematologia - Azienda Ospedaliera di Careggi" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Associazione Italiana di Immunogenetica e Biologia dei Trapianti (AIBT)" with 1 trials as a collaborator, "Associazione Italiana per la Ricerca sul Cancro" with 1 trials as a collaborator, "CML Advocates Network" with 1 trials as a collaborator and "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Cattedra di Ematologia - Azienda Ospedaliera di Careggi" are "Non-Hodgkin's Lymphoma" (4 trials), "Myelofibrosis" (3 trials), "Acute Lymphoblastic Leukemia" (2 trials), "Acute Myeloid Leukemia" (2 trials) and "Chronic Lymphocytic Leukemia" (2 trials). Many other conditions were trialed in "Cattedra di Ematologia - Azienda Ospedaliera di Careggi" in a lesser frequency.

Most popular intervention types in "Cattedra di Ematologia - Azienda Ospedaliera di Careggi" are "Drug" (24 trials), "Other" (7 trials), "Behavioral" (1 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Rituximab" (2 trials), "Venetoclax" (2 trials), "observation" (2 trials) and "rituximab [MabThera/Rituxan]" (2 trials). Other intervention names were less common.

The vast majority of trials in "Cattedra di Ematologia - Azienda Ospedaliera di Careggi" are 35 trials for "All" genders.

Currently, there are NaN active trials in "Cattedra di Ematologia - Azienda Ospedaliera di Careggi". undefined are not yet recruiting, 8 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Cattedra di Ematologia - Azienda Ospedaliera di Careggi, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Cattedra di Ematologia - Azienda Ospedaliera di Careggi, 1 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".